Inventor · disambiguated record
Jim R. Beitel
Also filed as: BEITEL JIM R
10 granted patents·1 pending application·100 citations·filing 2009–2020
90Inventor score
Top patents by PatentIndex Score
11 records- 0195US8232073B2Quantification of non-reducing end glycan residual compoundsCRAWFORD BRETT E·Filed 2009·Granted Jul 31, 2012·35 cites·15 claims
- 0294US9340822B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2014·Granted May 17, 2016·12 cites·23 claims
- 0394US8809009B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2012·Granted Aug 19, 2014·14 cites·16 claims
- 0494US8771974B2Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorderCRAWFORD BRETT E·Filed 2012·Granted Jul 8, 2014·16 cites·21 claims
- 0592US9915649B2Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVABIOMARIN PHARM INC·Filed 2016·Granted Mar 13, 2018·4 cites·34 claims
- 0692US9222120B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2014·Granted Dec 29, 2015·13 cites·21 claims
- 0790US9677116B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2015·Granted Jun 13, 2017·4 cites·30 claims
- 0888US10260084B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2017·Granted Apr 16, 2019·2 cites·12 claims
- 0975US10793894B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2019·Granted Oct 6, 2020·0 cites·20 claims
- 1072US2021025874A1Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2020·Application pending·0 cites
- 1169US10677786B2Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2018·Granted Jun 9, 2020·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Jim R. Beitel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →